valproic acid has been researched along with Anemia in 9 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Anemia: A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BACKGROUND Valproic acid is utilized for the management of various disease states, but coagulation changes, such as thrombocytopenia, can limit use." | 7.96 | Valproic Acid-Induced Thrombocytopenia-Related Spontaneous Systemic Bleeding. ( Johnston, JP; Nerenberg, SF, 2020) |
| "A 42-year-old man with human immunodeficiency virus (HIV) infection and a history of complex partial seizures developed severe anemia after the addition of valproic acid to his stable antiretroviral regimen of zidovudine, lamivudine, and abacavir." | 7.72 | Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. ( Antoniou, T; Arbess, G; Gough, K; Yoong, D, 2004) |
| "Valproic acid is an antiepileptic drug in widespread use." | 5.30 | Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. ( Neiderud, J; Stahl, MM; Vinge, E, 1997) |
| "BACKGROUND Valproic acid is utilized for the management of various disease states, but coagulation changes, such as thrombocytopenia, can limit use." | 3.96 | Valproic Acid-Induced Thrombocytopenia-Related Spontaneous Systemic Bleeding. ( Johnston, JP; Nerenberg, SF, 2020) |
| "A 42-year-old man with human immunodeficiency virus (HIV) infection and a history of complex partial seizures developed severe anemia after the addition of valproic acid to his stable antiretroviral regimen of zidovudine, lamivudine, and abacavir." | 3.72 | Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid. ( Antoniou, T; Arbess, G; Gough, K; Yoong, D, 2004) |
| "The purpose of this study was to determine the occurrence of leukopenia and other blood dyscrasias associated with psychiatric use of carbamazepine and valproate." | 3.69 | Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk. ( Baldessarini, RJ; Castillo, J; Kando, JC; Tohen, M; Zarate, C, 1995) |
| "A girl with intractable epilepsy who received high dose valproic acid showed bone marrow suppression, which improved after the end of valproic acid treatment and the administration of supportive treatments." | 3.69 | Bone marrow suppression induced by high dose valproic acid. ( Fujita, N; Ishimae, M; Kawaguchi, H; Kishi, T; Tanaka, T; Watanabe, K, 1994) |
| "Valproic acid is an antiepileptic drug in widespread use." | 1.30 | Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid. ( Neiderud, J; Stahl, MM; Vinge, E, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (44.44) | 18.2507 |
| 2000's | 1 (11.11) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Schoonjans, A | 1 |
| Maes, P | 1 |
| Ceulemans, B | 1 |
| Johnston, JP | 1 |
| Nerenberg, SF | 1 |
| Park, S | 1 |
| Hamel, JF | 1 |
| Toma, A | 1 |
| Kelaidi, C | 1 |
| Thépot, S | 1 |
| Campelo, MD | 1 |
| Santini, V | 1 |
| Sekeres, MA | 1 |
| Balleari, E | 1 |
| Kaivers, J | 1 |
| Sapena, R | 1 |
| Götze, K | 1 |
| Müller-Thomas, C | 1 |
| Beyne-Rauzy, O | 1 |
| Stamatoullas, A | 1 |
| Kotsianidis, I | 1 |
| Komrokji, R | 1 |
| Steensma, DP | 1 |
| Fensterl, J | 1 |
| Roboz, GJ | 1 |
| Bernal, T | 1 |
| Ramos, F | 1 |
| Calabuig, M | 1 |
| Guerci-Bresler, A | 1 |
| Bordessoule, D | 1 |
| Cony-Makhoul, P | 1 |
| Cheze, S | 1 |
| Wattel, E | 1 |
| Rose, C | 1 |
| Vey, N | 1 |
| Gioia, D | 1 |
| Ferrero, D | 1 |
| Gaidano, G | 1 |
| Cametti, G | 1 |
| Pane, F | 1 |
| Sanna, A | 1 |
| Germing, U | 1 |
| Sanz, GF | 1 |
| Dreyfus, F | 1 |
| Fenaux, P | 1 |
| Li, C | 1 |
| Su, L | 1 |
| Lao, M | 1 |
| Zhu, S | 1 |
| Ding, M | 1 |
| Antoniou, T | 1 |
| Gough, K | 1 |
| Yoong, D | 1 |
| Arbess, G | 1 |
| Tohen, M | 1 |
| Castillo, J | 1 |
| Baldessarini, RJ | 1 |
| Zarate, C | 1 |
| Kando, JC | 1 |
| Kishi, T | 1 |
| Fujita, N | 1 |
| Kawaguchi, H | 1 |
| Ishimae, M | 1 |
| Watanabe, K | 1 |
| Tanaka, T | 1 |
| Stahl, MM | 1 |
| Neiderud, J | 1 |
| Vinge, E | 1 |
| Hemingway, C | 1 |
| Leary, M | 1 |
| Riordan, G | 1 |
| Schlegal, B | 1 |
| Walker, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Integrated European Platform to Conduct Translational Studies in Myelodysplastic Syndromes Based on the EuroBloodNet Infrastructure[NCT04174547] | 8,670 participants (Anticipated) | Observational | 2019-09-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 other studies available for valproic acid and Anemia
| Article | Year |
|---|---|
Aggravation of valproic acid induced thrombocytopenia after the introduction of fenfluramine, a case report.
Topics: Anemia; Anticonvulsants; Fenfluramine; Humans; Thrombocytopenia; Valproic Acid | 2021 |
Valproic Acid-Induced Thrombocytopenia-Related Spontaneous Systemic Bleeding.
Topics: Anemia; Female; Hemorrhage; Humans; Middle Aged; Thrombocytopenia; Valproic Acid | 2020 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; | 2017 |
Anemia secondary to the use of sodium valproate for preventing postoperative seizures in a 79-year-old man: A case report.
Topics: Aged; Anemia; Anticonvulsants; Erythrocyte Transfusion; Humans; Liver Function Tests; Male; Neurosur | 2018 |
Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.
Topics: Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interaction | 2004 |
Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk.
Topics: Adolescent; Adult; Anemia; Carbamazepine; Depressive Disorder; Desipramine; Drug Therapy, Combinatio | 1995 |
Bone marrow suppression induced by high dose valproic acid.
Topics: Anemia; Bone Marrow; Cells, Cultured; Colony-Forming Units Assay; Depression, Chemical; Epilepsy; Fe | 1994 |
Thrombocytopenic purpura and anemia in a breast-fed infant whose mother was treated with valproic acid.
Topics: Anemia; Anticonvulsants; Breast Feeding; Epilepsy; Female; Humans; Infant; Infant, Newborn; Maternal | 1997 |
The effect of carbamazepine and sodium valproate on the blood and serum values of children from a third-world environment.
Topics: Adolescent; Anemia; Anticonvulsants; Black People; Carbamazepine; Child; Child, Preschool; Developin | 1999 |